Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis Through P16-Independent Mechanisms

Overview

Journal Transl Oncol

Specialty Oncology

Date 2015 Oct 27

PMID 26500029

Citations 5

Authors

Lia E De Faveri

Carolyn D Hurst

Jo-An Roulson

Henry Wood

Marta Sanchez-Carbayo

Margaret A Knowles

Emma J Chapman

Affiliations

Soon will be listed here.

Abstract

Urothelial carcinoma (UC) causes significant morbidity and remains the most expensive cancer to treat because of the need for repeated resections and lifelong monitoring for patients with non-muscle-invasive bladder cancer (NMIBC). Novel therapeutics and stratification approaches are needed to improve the outlook for both NMIBC and muscle-invasive bladder cancer. We investigated the expression and effects of B Lymphoma Mo-MLV Insertion Region 1 (BMI1) in UC. BMI1 was found to be overexpressed in most UC cell lines and primary tumors by quantitative real-time polymerase chain reaction and immunohistochemistry. In contrast to some previous reports, no association with tumor stage or grade was observed in two independent tumor panels. Furthermore, upregulation of BMI1 was detected in premalignant bladder lesions, suggesting a role early in tumorigenesis. BMI1 is not located within a common region of genomic amplification in UC. The CDKN2A locus (which encodes the p16 tumor suppressor gene) is a transcriptional target of BMI1 in some cellular contexts. In UC cell lines and primary tissues, no correlation between BMI1 and p16 expression was observed. Retroviral-mediated overexpression of BMI1 immortalized normal human urothelial cells (NHUC) in vitro and was associated with induction of telomerase activity, bypass of senescence, and repression of differentiation. The effects of BMI1 on gene expression were identified by expression microarray analysis of NHUC-BMI1. Metacore analysis of the gene expression profile implicated downstream effects of BMI1 on α4/β1 integrin-mediated adhesion, cytoskeleton remodeling, and CREB1-mediated transcription.

Citing Articles

Role of SIK1 in tumors: Emerging players and therapeutic potentials (Review).

Zhang X, Liu J, Zuo C, Peng X, Xie J, Shu Y Oncol Rep. 2024; 52(6).

PMID: 39422046 PMC: 11544583. DOI: 10.3892/or.2024.8828.

BMI1 promotes osteosarcoma proliferation and metastasis by repressing the transcription of SIK1.

Wang Q, Wu Y, Lin M, Wang G, Liu J, Xie M Cancer Cell Int. 2022; 22(1):136.

PMID: 35346195 PMC: 8961961. DOI: 10.1186/s12935-022-02552-8.

BMI1 activates P-glycoprotein via transcription repression of and enhances chemoresistance of bladder cancer cell.

Chen M, Zhou J, Wang P, Ye Y, Liu Y, Zhou J Aging (Albany NY). 2021; 13(14):18310-18330.

PMID: 34270461 PMC: 8351696. DOI: 10.18632/aging.203277.

Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1.

Jia Y, Ding X, Zhou L, Zhang L, Yang X Oncogene. 2020; 40(2):246-261.

PMID: 33122828 DOI: 10.1038/s41388-020-01486-7.

Doxycycline-induced exogenous Bmi-1 expression enhances tumor formation in a murine model of oral squamous cell carcinoma.

Kalish J, Tang X, Scognamiglio T, Zhang T, Gudas L Cancer Biol Ther. 2020; 21(5):400-411.

PMID: 32037955 PMC: 7515545. DOI: 10.1080/15384047.2020.1720485.

References

Liang W, Zhu D, Cui X, Su J, Liu H, Han J . Knockdown BMI1 expression inhibits proliferation and invasion in human bladder cancer T24 cells. Mol Cell Biochem. 2013; 382(1-2):283-91. PMC: 3771375. DOI: 10.1007/s11010-013-1745-0. View

Nagarajan P, Onami T, Rajagopalan S, Kania S, Donnell R, Venkatachalam S . Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene. 2009; 28(8):1053-62. PMC: 2648865. DOI: 10.1038/onc.2008.440. View

Wood H, Belvedere O, Conway C, Daly C, Chalkley R, Bickerdike M . Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Res. 2010; 38(14):e151. PMC: 2919738. DOI: 10.1093/nar/gkq510. View

Breuer R, Snijders P, Sutedja G, Sewalt R, Otte A, Postmus P . Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer. 2005; 48(3):299-306. DOI: 10.1016/j.lungcan.2004.11.026. View

Raaphorst F, van Kemenade F, Fieret E, Hamer K, Satijn D, Otte A . Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol. 1999; 164(1):1-4. DOI: 10.4049/jimmunol.164.1.1. View

Qiao B, Chen Z, Hu F, Tao Q, Lam A . BMI-1 activation is crucial in hTERT-induced epithelial-mesenchymal transition of oral epithelial cells. Exp Mol Pathol. 2013; 95(1):57-61. DOI: 10.1016/j.yexmp.2013.05.004. View

Sarkar S, Julicher K, Burger M, Della Valle V, Larsen C, Yeager T . Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res. 2000; 60(14):3862-71. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2005; 2(8):416-22. View

Knowles M, Hurst C . Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2014; 15(1):25-41. DOI: 10.1038/nrc3817. View

10.

Vonlanthen S, Heighway J, Altermatt H, Gugger M, Kappeler A, Borner M . The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001; 84(10):1372-6. PMC: 2363629. DOI: 10.1054/bjoc.2001.1791. View

11.

Glinsky G, Berezovska O, Glinskii A . Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115(6):1503-21. PMC: 1136989. DOI: 10.1172/JCI23412. View

12.

Chapman E, Kelly G, Knowles M . Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res. 2008; 6(7):1154-68. PMC: 3437422. DOI: 10.1158/1541-7786.MCR-07-2168. View

13.

Zhu D, Wan X, Huang H, Chen X, Liang W, Zhao F . Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells. Oncol Rep. 2013; 31(2):727-36. DOI: 10.3892/or.2013.2919. View

14.

Tateishi K, Ohta M, Kanai F, Guleng B, Tanaka Y, Asaoka Y . Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res. 2006; 12(23):6960-6. DOI: 10.1158/1078-0432.CCR-06-0449. View

15.

van der Lugt N, Domen J, Linders K, van Roon M, Te Riele H, van der Valk M . Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994; 8(7):757-69. DOI: 10.1101/gad.8.7.757. View

16.

Shafaroudi A, Mowla S, Ziaee S, Bahrami A, Atlasi Y, Malakootian M . Overexpression of BMI1, a polycomb group repressor protein, in bladder tumors: a preliminary report. Urol J. 2008; 5(2):99-105. View

17.

Kreso A, van Galen P, Pedley N, Lima-Fernandes E, Frelin C, Davis T . Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2013; 20(1):29-36. DOI: 10.1038/nm.3418. View

18.

Saito M, Handa K, Kiyono T, Hattori S, Yokoi T, Tsubakimoto T . Immortalization of cementoblast progenitor cells with Bmi-1 and TERT. J Bone Miner Res. 2004; 20(1):50-7. DOI: 10.1359/JBMR.041006. View

19.

Wang Y, Zhe H, Ding Z, Gao P, Zhang N, Li G . Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg. 2012; 36(5):1189-1194. DOI: 10.1007/s00268-012-1514-3. View

20.

Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A . Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia. 2007; 21(5):1116-22. DOI: 10.1038/sj.leu.2404623. View